An Investigation Into The Impact Of Enteric Coated Of Aspirin In Patients With Newly Diagnosed Ischemic Stroke.

Hamad Medical Corporation42 enrolled

Overview

Uncertainty remains regarding the impact of enteric-coated (EC) aspirin as it relates to the reduction of CV risk. We hypothesize that EC formulation based on the previous report may blunt aspirin response as evidenced by reduced Thromboxane A2 (TXA 2) levels in diabetic patients.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Stroke, Ischemic

Interventions

Enteric Coated Aspirin TabletDRUG

Study participants will be assigned to receive either EC Aspirin and will be required to continue taking them throughout the study (three days).

Plain AspirinDRUG

Study participants will be assigned to receive either Plain Aspirin and will be required to continue taking them throughout the study (three days).

Eligibility

Sex: ALLMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Newly diagnosed ischemic stroke who are just about to start aspirin. 2. No prior history of cardiovascular morbidity (including ischemic heart disease, chronic kidney disease, peripheral vascular disease) 3-18- 75 years. 4-Patients with ischemic stroke who underwent reperfusion intervention (catheter-directed thrombolysis and/or thrombectomy) regardless of the time of presentation (i.e within or outside the therapeutic window as the managing stroke deem fit. Exclusion Criteria: 1. Concomitant antiplatelet therapy (irrespective of the duration of the treatment). 2. Patients on any prostaglandins related medications (non-steroidal anti-inflammatory drugs, misoprostol, and other ant secretory drugs among others). 3. Any salicylate-containing supplements. 4. Patients on the NG tube will be excluded from the study

Locations (1)

Hamad Medical Corporation

Doha, Qatar

Outcomes

Primary Outcomes

Incidence of Aspirin non-responders.

Aspirin nonresponsiveness is defined as a level of residual serum TXB2 associated with elevated thrombotic risk (\<99.0% inhibition or TXB2 \>3.1 ng/ml) after 3 daily aspirin doses

Time frame: At "Day 3"

Secondary Outcomes

Incidence of Gastrointestinal bleeding consequent upon aspirin therapy.

Major and minor GIT bleeding

Time frame: After three daily aspirin doses ( at "Day 3")

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.